Reimbursed Care Access in Slovenia

Currently classified as a strictly controlled substance under Slovenia’s drug control framework (Uredba o razvrstitvi prepovedanih drog / ZPPPD) with no authorised medical use outside of approved clinical research. Routine medical prescription and public reimbursement are not permitted; access is limited to formally approved clinical trials or special research import authorisations. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any therapeutic use in Slovenia would be possible only within sanctioned clinical trials or under very narrow, case‑by‑case research/compassionate‑use arrangements. # #

Esketamine nasal spray (Spravato) holds a marketing authorization valid across the European Union (EMA authorisation 18 December 2019), which means it may legally be placed on the Slovenian market and prescribed by authorised clinicians. #

Regulatory & reimbursement framework in Slovenia: medicines are reimbursed through the national Health Insurance Institute (Zavod za zdravstveno zavarovanje Slovenije, ZZZS) after evaluation by a national Pharmaceutical Reimbursement Commission and placement on the ZZZS positive list (or intermediate/negative lists determine co‑payment levels). Whether a given authorised medicine is publicly reimbursed depends on that ZZZS decision, which evaluates clinical effectiveness, cost and cost‑effectiveness; placement on the positive list is required for routine public reimbursement. In practice this produces heterogeneity: an EU‑authorised drug can be legally prescribed but still require out‑of‑pocket payment or private insurance if it is not placed on the ZZZS positive list. # #

Clinical indications and delivery: EMA and product labelling restrict esketamine to specific indications (adjunctive treatment in adults with treatment‑resistant major depressive disorder and for certain acute severe depressive presentations where authorised). Use requires administration in a supervised clinical setting consistent with REMS‑type safety requirements; in Slovenia that means administration is typically hospital‑ or clinic‑based under specialist oversight. #

Reimbursement reality (Slovenia, as of 20 February 2026): there is authoritative EU marketing authorisation but reimbursement in Slovenia is conditional on ZZZS positive‑list inclusion. Public sources describing the ZZZS reimbursement pathway are available (see WHO summary), but I was not able to find a publicly posted ZZZS positive‑list decision explicitly confirming nationwide public reimbursement of Spravato in Slovenia as of 20 February 2026; therefore clinicians/patients should check the current ZZZS positive list or contact ZZZS/hospital pharmacy directly for the live status and any prior‑authorisation requirements. # #

Ketamine is an authorised and widely used anaesthetic and analgesic in Slovenian hospitals and is supplied and reimbursed as a standard hospital medicine for its licensed indications (general anaesthesia, analgesia) under ordinary hospital procurement and reimbursement mechanisms. The clinical product monographs for intravenous/intramuscular ketamine preparations describe anesthetic/analgesic indications consistent with international practice. # #

Off‑label psychiatric use (e.g., sub‑anaesthetic ketamine infusions for depressive disorders) is practised internationally and may be provided in Slovenia by hospital clinics or private providers, but such off‑label psychiatric uses do not automatically carry routine public reimbursement. Public reimbursement would require an approved indication and/or inclusion in the ZZZS reimbursement lists or commissioning by public hospitals; otherwise psychiatric ketamine programs are frequently self‑funded by patients or covered by private insurers on a case‑by‑case basis. Clinicians seeking to deliver ketamine for psychiatric indications should confirm institutional policies, national guidance and the ZZZS reimbursement position. #

Currently classified as a strictly controlled substance under Slovenia’s drug scheduling regulations with no authorised medical use outside approved clinical research; access is limited to sanctioned trials or tightly controlled research import/export permits. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Slovenia. Any possession, distribution or clinical use outside approved trials is prohibited. # #

Currently classified under Slovenia’s controlled‑substances regime with no authorised medical indication and no routine public reimbursement; lawful therapeutic use is limited to formally approved clinical research protocols (if any) or exceptional, case‑by‑case permissions. Note: some non‑official sources and academic commentary discuss ‘unofficial’ or religious‑context practices, but these do not constitute recognised, reimbursed medical pathways in Slovenia. # #

The primary psychoactive constituent of ayahuasca (DMT) and the beverage itself fall under Slovenia’s controlled‑substance laws; there is no authorised medical use or public reimbursement outside approved clinical research. Use in religious or ritual contexts has been discussed in secondary sources but is not an authorised, reimbursed medical pathway. # #

Mescaline and peyote/mescaline‑containing preparations are controlled under Slovenian drug scheduling with no authorised medical use outside properly authorised clinical trials. Routine clinical prescribing and public reimbursement are not available. # #

The 2C family (including 2C‑B and related 2C‑X compounds) are explicitly controlled in Slovenia’s scheduling updates and are illegal outside of approved research; there is no authorised medical indication or public reimbursement for therapeutic use. # #